J&J to pay $181 million to settle improper marketing claims
(Reuters) - Johnson & Johnson (JNJ.N: Quote) said it has agreed to pay $181 million to resolve consumer fraud claims by 36 U.S. states and the District of Columbia that it improperly marketed its Risperdal antipsychotic drug for unapproved uses.
The diversified healthcare company, which has also been targeted by federal authorities for separate but related criminal allegations, said it had already set aside funds to cover the civil settlement. The funds will be divided among the states participating in the agreement, announced on Thursday.
The company said the settlement was not an admission of wrongdoing.
(Reporting by Bill Berkrot and Ransdell Pierson; editing by John Wallace)
© Thomson Reuters 2017 All rights reserved.